Table 2 Clinical and treatment related characteristics of respondents at hospitals of southwest Shewa zone, Oromia, central Ethiopia, 2024 (N = 353).
Variables | Category | Frequency (%) |
|---|---|---|
Current anti-epileptic drugs | Phenobarbitone | 151 (42.8) |
Phenytoin | 62 (17.6) | |
Sodium valproate | 8 (2.3) | |
Carbamazepine | 30 (8.5) | |
Phenobarbitone + phenytoin | 53 (15.0) | |
Phenobarbitone + sodium valproate | 17 (4.8) | |
Phenobarbitone + carbamazepine | 26 (7.4) | |
Phenytoin + sodium valproate | 3 (0.8) | |
Phenytoin + carbamazepine | 3 (0.8) | |
Medication other than anti-epileptic drugs | No | 315 (89.2) |
Yes | 38 (10.8) | |
Type of medications other than anti-epileptic drugs | Risperidone | 9 (2.5) |
Haloperidol | 5 (1.4) | |
Olanzapine | 1 (0.3) | |
Amitriptyline | 8 (2.3) | |
Chlorpromazine | 4 (1.1) | |
Nifedipine | 3 (0.8) | |
Amlodipine | 6 (1.8) | |
Fluoxetine | 2 (0.6) | |
Number of anti-epileptic drugs prescribed | One | 252 (71.4) |
Two | 101 (28.6) | |
Comorbid illness | No | 315 (89.2) |
Yes | 38 (10.8) | |
Reported side effects | No | 284 (80.5) |
Yes | 69 (19.5) | |
Duration on treatment | 3 months–1 year | 46 (13.0) |
1–3 years | 109 (30.9) | |
3–5 years | 114 (32.3) | |
> 5 years | 84 (23.8) |
